Origent Data Sciences Announces Appointment of Dr. David L. Ennist as President and CEO

Veteran Scientist Positioned to Lead Origent’s Efforts to Optimize and Rescue Clinical Trials


VIENNA, Virginia, November 23, 2019 – Origent Data Sciences, Inc. today announced that its Board of Directors has appointed Dr. David L. Ennist as President and Chief Executive Officer effective immediately. Dr. Ennist has served continuously as Chief Science Officer since Origent’s inception in 2013.

Mike Keymer, who has held the role of President & CEO since 2013, will continue to serve on the Board of Directors and remain actively involved in supporting the Origent leadership team, which includes Dr. Ennist and Chief Data Science Officer Danielle Beaulieu.

“We are fortunate to have someone of Dave’s caliber and experience to lead Origent,” said Keymer. “I have been grateful for his contributions as Chief Science Officer and his counsel during my own tenure as CEO. He is the perfect leader to execute Origent’s move into the drug rescue space, as we work with our partners to bring new therapies to the market to treat neurodegenerative diseases such as amyotrophic lateral sclerosis, Parkinson’s Disease, Huntington’s Disease, Alzheimer’s Disease, and others. I look forward to continuing to support and collaborate with Dave during this exciting next stage of Origent’s growth.”

Fabian Rosado, Chairman of Origent, said, “Origent is indebted to Mike for his contributions as founding CEO of Origent, and his service and dedication over the last seven years. Mike created a culture of integrity, innovation, and earned trust at Origent, and helped the company push the boundaries of machine learning, AI, and computational science in support of drug development and clinical trials. Dr. Ennist will now build on top of the foundation that Mike created as we pursue our mission of rescuing and bringing to market new drug therapies which failed their initial attempts at registration. Origent’s future success will depend on our ability to synthesize complex information across data science, medical science, and drug development. Dr. Ennist is perfectly aligned at the intersection of these domains, and has the right operational, scientific, and managerial experience to lead Origent in our next chapter.”

Ennist said, “I believe we have a unique opportunity to rejuvenate therapeutics in multiple neurodegenerative indications that have languished in clinical development. I am honored that the Origent board has selected me to lead Origent into its next chapter and am grateful that Mike Keymer will continue to provide sage advice in his role as Director. With our amazing team, I know Origent will continue to be a leader in the application of machine-learning for improving the efficiency of clinical trials.”

About Origent Data Sciences

Origent is dedicated to rescuing failed clinical trials and reducing drug development risks through better foresight. Origent’s scientists are experts in the development and application of predictive models that are designed to anticipate and predict the dynamics of individual patients. By modeling patient-level dynamics rather than the characteristics of a population, Origent’s tools uncover a deep level of insight that provides greater knowledge from clinical trial data. For additional information about Origent, please visit our website at https://www.origent.com.


Share This